Sequana Medical announces results of Annual and Extraordinary General Meetings of Shareholders
Ghent, Belgium, 22 May 2025 - Sequana Medical NV(Euronext Brussels: SEQUA) (the "Company" or "SequanaMedical"), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, announces today that all proposed resolutions submitted to the Annual and Extraordinary General Meetings of Shareholders were approved at the meetings held today at 09:00 am CEST.
The items on the agendas of the meetings included (among other) the approval of a number of resolutions relating to the financial year ended 31 December 2024, the approval of the remuneration report, the re-appointment of directors, certain approvals in accordance with Article 7:151 of the Belgian Companies and Associations Code, the renewal of the authorization to the Board of Directors to increase the share capital within the framework of the authorised capital, the approval of the issuance of the "2025 Share Options" (in the form of new subscription rights), as well as the approval of the issuance of the "GEM Warrants".
The minutes of the shareholders' meetings, as well as the revised versions of the Company's articles of
association, can be accessed on the Company's website.
For more information, please contact:
Sequana Medical
Investor relations
E: IR@sequanamedical.com
T: +32 9 292 8065
About Sequana Medical
Sequana Medical NV is a pioneer in treating fluid overload, a serious and frequent clinical complication in patients with liver disease, heart failure and cancer. This causes major medical issues including increased mortality, repeated hospitalizations, severe pain, difficulty breathing and restricted mobility. Although diuretics are standard of care, they become ineffective, intolerable or exacerbate the problem in many patients. There are limited effective treatment options, resulting in poor clinical outcomes, high costs and a major impact on their quality of life. Sequana Medical is seeking to provide innovative treatment options for this large and growing "diuretic resistant" patient population. alfapump® and DSR® are Sequana Medical's proprietary platforms that work with the body to treat diuretic-resistant fluid overload, and are intended to deliver major clinical and quality of life benefits for patients, while reducing costs for healthcare systems.
The Company received US FDA approval for the alfapump System for the treatment of recurrent or refractory ascites due to liver cirrhosis in December 2024, following the grant of FDA Breakthrough Device Designation in 2019. Sequana Medical intends to start US commercialisation in Q3 2025 through a small specialty sales force that it will establish to target the 90 US liver transplant centers that perform 95% of liver transplants.
Results of the Company's RED DESERT and SAHARA proof-of-concept studies in heart failure published in European Journal of Heart Failure in April 2024 support DSR's mechanism of action as breaking the vicious cycle of cardiorenal syndrome. All three patients from the non-randomized cohort of MOJAVE, a US randomized controlled multi-center Phase 1/2a clinical study, have been successfully treated with DSR, resulting in a dramatic improvement in diuretic response and virtual elimination of loop diuretic requirements1.
Sequana Medical is listed on the regulated market of Euronext Brussels.
Important Safety Information: For important safety information regarding the alfapump® system, see https://www.sequanamedical.com/wp-content/uploads/ISI.pdf.
The alfapump® System is currently not approved in Canada.
DSR® therapy is still in development and is currently not approved in any country. The safety and effectiveness of DSR® therapy has not been established.
Note: alfapump® and DSR® are registered trademarks.
Forward-looking statements
This press release may contain predictions, estimates or other information that might be considered forward-looking statements. Such forward-looking statements are not guarantees of future performance. These forward-looking statements represent the current judgment of Sequana Medical on what the future holds, and are subject to risks and uncertainties that could cause actual results to differ materially. Sequana Medical expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release, except if specifically required to do so by law or regulation. You should not place undue reliance on forward-looking statements, which reflect the opinions of Sequana Medical only as of the date of this press release.
1 Data reported in press release of March 25, 2024; mean increase of 326% in six-hour urinary sodium excretion at 3 months follow up vs baseline, and 95% reduction of loop diuretics over same period
Attachments
- 20250522 Sequana Medical - Press release Results AGM EGM (NL) (https://ml-eu.globenewswire.com/Resource/Download/1596ce01-a246-4b69-866b-3bd3127c7885)
- 20250522 Sequana Medical - Press release Results AGM EGM (ENG) (https://ml-eu.globenewswire.com/Resource/Download/81b50a7e-781e-497b-ac1c-c4bf8822cd3c)
